Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial
11 janv. 2023 07h00 HE
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of medicines to treat...